Can Cannabis Reduce Aggression and Agitation in Dementia? 

Agitation and aggression are among the most distressing behavioural and psychological symptoms of dementia (BPSD), affecting up to 90% of people with Alzheimer’s and related conditions. Standard medications such as antipsychotics and benzodiazepines can help but often carry significant risks, including sedation, falls, and cardiovascular events. 

Emerging evidence suggests that cannabis-based compounds, particularly THC and CBD, may offer an alternative by targeting the brain’s endocannabinoid system, which regulates mood, arousal, and inflammation. While findings are promising, experts caution that evidence remains preliminary, and cannabis is not yet recommended by the NHS or NICE for dementia-related behaviours. 

How Cannabinoids May Influence Behaviour 

The endocannabinoid system helps regulate emotional stability and neural communication. Two key receptors, CB1 (in the brain) and CB2 (in immune cells and microglia), are involved in behavioural control and inflammation. 

• THC, a CB1 partial agonist, can calm hyperactive neural circuits that drive agitation, though higher doses may impair attention or cause drowsiness. 

• CBD interacts more indirectly, reducing inflammation via CB2 and modulating serotonin (5-HT1A) receptors. This dual action may help stabilise mood, reduce irritability, and improve sleep, all key factors in dementia-related aggression. 

According to a 2024 review in Frontiers in Psychiatry, this complementary mechanism between THC and CBD could explain why balanced formulations are often better tolerated than THC alone. 

Clinical Evidence: What Recent Studies Show (2020–2025) 

THC: CBD Combination Studies 

The STAND trial in the UK evaluated Sativex® (nabiximols), a 1:1 THC: CBD oromucosal spray, in people with Alzheimer’s disease and severe agitation. The feasibility results, published in 2025, found improved agitation scores and good tolerability, laying groundwork for a larger study (PMC12143470). 

Similarly, a Swiss observational study by Pautex et al. (2022) followed 19 patients with advanced dementia using low-dose THC: CBD oil and reported sustained reductions in agitation and rigidity with minimal side effects (PubMed 36247984). 

Bianchi et al. (2023) observed comparable improvements in 20 elderly patients using oral THC/CBD oil, including decreased aggression and reduced need for sedatives (PubMed 37293434). 

CBD-Dominant Preparations 

A double-blind randomised trial by Hermush et al. (2022) tested Avidekel oil (rich in CBD with trace THC) and found significant reductions in agitation on the Cohen-Mansfield Agitation Inventory (CMAI) compared with placebo (PubMed 36148467). 

A 2025 review from the Journal of Psychopharmacology also noted consistent benefits across small studies using CBD-dominant oils in older adults, with fewer side effects than antipsychotics (SAGE Journals). 

THC-Focused Case Series 

At the University of Chicago, clinicians reported 79% caregiver-rated improvement in agitation, aggression, and irritability among dementia patients given low-dose THC gummies. Most adverse events were mild and temporary (University of Chicago Psychiatry, 2023). 

Evidence Synthesis: Reviews And Meta-Analyses 

Systematic reviews continue to highlight cautious optimism. A meta-analysis by Kuharic et al. (2021) found “low-certainty but measurable” benefits of cannabinoids in reducing agitation and aggression across small, heterogeneous trials (PubMed 34532852). 

The Broers et al. (2024) review in Frontiers in Psychiatry concluded that THC may help agitation and spasticity, while CBD contributes to mood stabilisation and better sleep, potentially lowering aggression levels (PubMed 38447959). 

Together, these findings suggest that cannabinoids can moderately reduce BPSD symptoms, but that larger, longer studies are needed for confirmation. 

UK Guidance: NICE, NHS, And Alzheimer’s Society 

According to NICE guidance NG97, behavioural interventions remain first-line for agitation and aggression, with drug treatments reserved for severe distress or risk of harm. The NICE NG144 guideline on cannabis-based medicinal products states that cannabinoids should only be prescribed by specialists and are not currently indicated for dementia. 

The NHS and Alzheimer’s Society UK echo this position: some studies show potential benefits, but evidence remains early-stage and insufficient for clinical use. The WHO also recognises cannabinoid research as promising but not yet ready for medical application in dementia. 

Safety and Tolerability 

Across studies, low-dose and balanced THC: CBD preparations appear safe and well tolerated in older adults. Reported side effects include mild sedation, dizziness, or confusion, typically resolving with dose adjustment. No serious cardiovascular or liver toxicity has been reported in the available RCTs. Long-term cognitive safety remains under study, with ongoing trials such as Bartschi et al. (2023) evaluating isolated CBD’s neuroendocrine and behavioural effects over 12 weeks. 

Clinical Bottom Line 

• THC: CBD oils show early evidence of reducing agitation and aggression in dementia. 

• CBD-dominant formulations appear especially well tolerated and may improve mood and sleep. 

• Evidence remains modest; benefits are measurable but not definitive. 

• NICE and NHS do not currently recommend cannabis for dementia-related behavioural symptoms. 

• Specialist oversight is essential if considered for compassionate or research-based use. 

Educational Context: AlleviMed 

AlleviMed provides public education about medical cannabis regulation and clinical frameworks in the UK. It explains how cannabis-based medicinal products are assessed by the MHRA and licensed under Home Office regulations. AlleviMed’s materials clarify that while early dementia trials are underway, cannabis is not licensed for agitation or aggression management, and all potential use must follow specialist review. 

Takeaway 

Cannabis-based treatments, especially THC: CBD combinations, are showing early promise for easing agitation and aggression in dementia. The likely mechanism involves restoring balance in the brain’s endocannabinoid and serotonin systems, reducing hyperactivity and inflammation. 

However, as noted by NICE, NHS, and Alzheimer’s Society UK, clinical evidence remains limited, and cannabis-based medicines should only be considered under specialist supervision within research or compassionate contexts. Ongoing UK studies such as the STAND trial will be key in determining whether cannabinoids can safely and effectively improve behavioural symptoms in dementia care.